Tag: 上海哪里还有弄堂女2020

Understudy Joshua Dela Cruz Will Temporarily Take the Lead in Broadway’s Aladdin

first_img Aladdin Joshua Dela Cruz(Photo courtesy of Disney Theatrical Productions) Related Shows Aladdin understudy Joshua Dela Cruz will take center stage in the Disney musical on Broadway. He takes on the title role temporarily beginning February 14. Original star Adam Jacobs will take his final bow at the New Amsterdam Theatre on February 12 prior to reprising his performance in the national tour beginning April 11 in Chicago.A full-time replacement for Jacobs will be announced at a later date.Dela Cruz made his Broadway debut in the Casey Nicholaw-helmed Aladdin. His additional credits include Here Lies Love off-Broadway and Merrily We Roll Along at New York City Center.The current cast of Aladdin also includes Tony winner James Monroe Iglehart as Genie, Courtney Reed as Jasmine, Clifton Davis as Sultan, Jonathan Freeman as Jafar, Brian Gonzales as Babkak, Brad Weinstock as Omar, Steel Burkhardt as Kassim and Don Darryl Rivera as Iago.center_img View Comments from $57.50last_img read more

Read More
Packaging, not yield, may be problem for nasal-spray H1N1 vaccine

first_imgJul 30, 2009 (CIDRAP News) – While most vaccine manufacturers have reaped below-average crops of H1N1 influenza vaccine virus from the eggs in which they’re grown, MedImmune Inc. has a different problem: high virus yields, but a potential shortage of the devices used to spray the vaccine into the nose.The company has produced more than 20 million bulk doses of the vaccine, well above the 12.8 million ordered so far by the US government, and has the capacity to make 205 million bulk doses, said Ben Machielse, executive vice president of operations, in an interview this week.But he said the company has the capability to put only 41 million doses in sprayers, so it is looking into the possibility of using droppers instead—an option that would require additional regulatory review but may permit making more vaccine available sooner. The Maryland-based company, part of AstraZeneca, makes the seasonal vaccine FluMist, which uses a live but weakened virus.The other manufacturers that have H1N1 vaccine orders from the Department of Health and Human Services (HHS)—Sanofi Pasteur, Novartis, GlaxoSmithKline (GSK), and CSL Biotherapies—have reported that their virus yields so far have been half or less of what they usually get when growing seasonal flu vaccines. (Yesterday an HHS official said yields have improved somewhat, but gave no details.)What the low yields mean for production expectations has been unclear. Three of the manufacturers (Sanofi, Novartis, and GSK), when contacted recently by CIDRAP News, declined to say how many doses they expect to make or how many have been ordered by HHS. A Bloomberg News report yesterday, citing Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said Novartis is responsible for 45% percent of the supply, while Sanofi will provide 26% and CSL will make 19%.Meanwhile, MedImmune is getting yields as good as or better than it reaps with seasonal vaccine, according to Machielse. “Given the fact that you need a very, very small dose of FluMist, we get a yield of about 80 doses per egg for this strain, and normally the seasonal strain has a yield of 60 to 100 doses per egg,” he said.MedImmune’s better yields may have to do with the fact that the company is using a different seed strain of H1N1, according to Machielse. The injectable-vaccine makers reportedly have been working with a strain developed at New York Medical College. He said MedImmune developed its own strain, combining genes from a wild-type H1N1 virus with the “backbone” genes of the virus used in FluMist.Machielse said HHS officials have expressed interest in ordering additional MedImmune doses beyond the initial 12.8 million but haven’t done so yet. In anticipation of a possible need to supply more doses than it has sprayers for, the company is looking into the dropper option.”The initial clinical development of FluMist was based on dropper administration, so we have a lot of clinical data on dropper administration,” he said. “We’ve contacted BARDA [HHS’s Biological Advanced Research and Development Agency], FDA [the Food and Drug Administration], and the National Vaccine Program Office, and they’re working with us to define a regulatory pathway to get a dropper device approved as soon as possible. We have a rough outline of what needs to be done, and we’re now in discussion with FDA to fine-tune it.”He said the company has told federal officials it could potentially have multidose droppers of its vaccine ready starting in early October. “We are currently working through all the details with suppliers, FDA, and BARDA to see what needs to be done to get to that point, but there are no guarantees because there are many parties involved,” he added.William Schaffner, MD, an immunization expert and chair of the Department of Preventive Medicine at Vanderbilt University in Nashville, said increased availability of MedImmune’s vaccine could help in the effort to immunize children against the new virus. Yesterday the CDC’s immunization advisory committee recommended vaccination for young people from 6 months through 24 years old, along with several other groups.”As a company they’ve really focused on children, so there’s a real potential this could be used widely not only in pediatricians’ offices, but if there are a number of school-based flu immunization programs, FluMist is vastly better than injectable vaccine in a school-based program,” Schaffner said.He said the vaccine, being needle-free, is much easier to administer in large numbers than injectable vaccines.The seasonal version of FluMist is considerably more expensive than injectable flu vaccines. But Schaffner noted that the H1N1 vaccines are being purchased by the federal government, so the cost for recipients or their insurers will mainly be the administrative expense.The administrative costs may be a barrier to school-based immunization programs, which are typically run by local health departments and take “a fair amount of preparation,” Schaffner added.As for possible adult use of MedImmune’s H1N1 vaccine, Schaffner noted that seasonal FluMist has not been used very widely in adults. It is approved for healthy people from ages 2 through 49.”People who have underlying illnesses can’t take FluMist,” Schaffner said. That would appear to rule out one of the groups the CDC committee targeted for H1N1 vaccination: those between 25 and 64 who have chronic medical conditions.last_img read more

Read More
SIS Product Director Paul Witten: Assessing the broadcast and betting scene within racing at #boscon2017

first_img SIS grows Latin American footprint through Betcris deal August 12, 2020 Share Submit Richard FitzGerald steps down as RMG CEO August 6, 2020 StumbleUpon Related Articles SBC Magazine Issue 10: Kaizen Gaming rebrand and focus for William Hill CEO August 25, 2020 Share To mark the start of the Betting on Sports conference, SIS Product Director Paul Witten, part of the ‘After the off – Opportunities in live betting’ racing session at the event, spoke to SBC News about what he’s looking forward to at #boscon2017 and what sports partnership has stood out over the last 12 months.SBC: Why is it important for you to speak at Betting on Sports?PW: Betting on Sports is a fantastic opportunity for SIS to speak with leading industry figures about the current broadcast and betting scene within horseracing and greyhounds.Specifically, the panel ‘After the Off’ will go into depth about the current opportunities and challenges within in-play betting on horse racing. We believe in-play betting will revolutionise the market. It will be fascinating to see how the panel reacts and hear their opinions on the future of the industry.SBC: What are you looking forward to at Betting on Sports?PW: It’ll be great to hear how various leading industry figures see sports betting progressing, in the areas of product, regulation, and technology. SIS operates within various verticals and we’re always looking to offer operators an improved product.We hope to take away new opinions and ideas from the panel sessions and people that we meet, as well as share our long-standing knowledge of the sector and vision for the industry in the coming years.SBC: Where can betting work together more closely with sport?PW: I’d like to see operators, suppliers and sporting bodies come together more on scheduling to improve the round the clock service that punters increasingly desire, mainly by helping grow the number of fixtures at times that suit the casual bettor.SBC: What sports betting partnership has stood out in the past 12 months?PW: It seems this season has been the tipping point for foreign operators to involve themselves with major football shirt sponsorships in the Premier League. It’s great to see that these companies see the value of the UK and its sports offering.It’s also been interesting to see an increased interest in the likes of cricket and rugby union by betting firms. I expect to see this trend continue into the likes of horse racing and greyhounds as operators realise the benefits of incorporating high-quality content onto their platforms.SBC: Describe your perfect sporting eventPW: It would have to be seeing England beat New Zealand in a Rugby World Cup final at a roaring Twickenham. After our struggles a couple of years ago, it would also add to the occasion if we can get our own back on the likes of Australia and Wales on the road to the final.last_img read more

Read More